{
    "title": "115_hr5687",
    "content": "The Act is titled the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs under the Federal Food, Drug, and Cosmetic Act. The Secretary may issue an order requiring the holder of a covered application to implement technologies for drug packaging or disposal to mitigate abuse or misuse, including reducing the availability of unused drugs. The Secretary must consult before issuing such an order. The Secretary may issue an order requiring the holder of a covered application to implement technologies for drug packaging or disposal to mitigate abuse or misuse, including reducing the availability of unused drugs. The order cannot be issued without prior consultation with relevant stakeholders. Technologies, controls, or measures required must be proportionate to the specific risk of abuse or misuse of the drug listed in the covered application. The Secretary may issue an order requiring the holder of a covered application to implement technologies for drug packaging or disposal to mitigate abuse or misuse. The order must be proportionate to the specific risk of abuse or misuse of the drug listed in the covered application and not unduly burdensome on patient access. The technologies, controls, or measures should reduce the risk of abuse or misuse of the drug. An order issued by the Secretary may provide options for implementing technologies, controls, or measures to reduce the risk of drug abuse or misuse. It may also reference standards for packaging or disposal from an official compendium. The Secretary's order may incorporate standards for packaging or disposal from an official compendium, established by a recognized standard development organization, or described on the FDA's website. The Secretary may issue an order applying to a pharmacological class based on concerns about drug abuse or misuse, after consulting stakeholders. Holders of covered applications must submit proposed changes to comply with the order within 180 days. The Secretary may issue an order for a pharmacological class due to drug abuse concerns. Holders of covered applications must submit proposed changes within 180 days, or a longer period specified by the Secretary. The holder of a covered application must submit requested alternative dates within 60 days of an order being issued. Changes approved in a supplement must be implemented within 90 days of approval or a longer period specified by the Secretary. The holder of a covered application must implement approved changes within 90 days of approval or a longer period determined by the Secretary. The holder of a covered application may request a longer period for implementation, and propose alternative technologies, controls, or measures supported by data and information. The holder of a covered application may propose alternative technologies, controls, or measures supported by data to mitigate the risk of drug abuse or misuse. Disputes regarding submitted supplements can be appealed by the holder. The holder of a covered application can propose alternative technologies, controls, or measures to mitigate drug abuse or misuse. Disputes related to submitted supplements can be appealed by the holder using specified procedures. The term 'covered application' refers to drug applications for opioids listed in schedule II or III under the Controlled Substances Act. 'Relevant stakeholders' may include scientific experts and drug manufacturers. The term 'relevant stakeholders' may include scientific experts, drug manufacturers, wholesalers, payers, health care providers, pharmacists, pharmacies, poison centers, and representatives from various government agencies and organizations. The curr_chunk discusses prohibited acts related to drugs approved under a covered application. It involves an amendment to the Federal Food, Drug, and Cosmetic Act. The stakeholders involved include the National Institutes of Health, CDC, Medicare & Medicaid Services, DEA, Consumer Product Safety Commission, addiction specialists, and patient/caregiver groups. The curr_chunk amends the content requirements for an Abbreviated New Drug Application under the Federal Food, Drug, and Cosmetic Act. It includes provisions related to drugs containing opioids. The curr_chunk adds new requirements for drug applications involving opioids, including proposed technologies for packaging and disposal to enhance safety measures. The curr_chunk amends Section 505(j)(4) of the Federal Food, Drug, and Cosmetic Act to include new requirements for drug applications related to opioids, such as proposed technologies for packaging and disposal to improve safety measures. The amendment to Section 505(j)(4) of the Federal Food, Drug, and Cosmetic Act now includes new requirements for drug applications concerning opioids, specifically addressing technologies, controls, or measures related to packaging and disposal for improved safety measures. The amendment to Section 505(j)(4) of the Federal Food, Drug, and Cosmetic Act now includes new requirements for drug applications concerning opioids, specifically addressing technologies, controls, or measures related to packaging and disposal for improved safety measures. Any labeling describing technologies, controls, or measures related to packaging or disposal intended to mitigate the risk of abuse or misuse of a drug product that is subject to an abbreviated new drug application. The labeling for drug products subject to an abbreviated new drug application must not be seen as changes to labeling not allowed under the Act. The labeling for drug products under an abbreviated new drug application must not be construed as changes that would prevent approval of the application. The labeling for drug products under an abbreviated new drug application must not be construed as changes that would prevent approval of the application. Covered applications under section 505 of the Federal Food, Drug, and Cosmetic Act should not limit the type of data the Secretary of Health and Human Services may request. The Comptroller General of the United States must submit a report within 12 months of the enactment of this Act. The Comptroller General of the United States will submit a report to Congress within 12 months of the enactment of this Act, containing information on the effectiveness of in-home controlled substance disposal products and ways to improve their use by patients and consumers. The report will include information on disposal products and packaging technologies for controlled substances, barriers to their use, and federal oversight of in-home disposal products. The report will detail federal oversight of in-home controlled substance disposal products, including identification of overseeing agencies, recommended disposal methods, and the effectiveness of prevention measures against diversion of prescribed substances. The report will include a description of federal oversight of controlled substance packaging technologies, identifying overseeing agencies and recommended technologies such as unit dose packaging or packaging with set durations. The report will also provide recommendations on site-of-use controlled substance disposal products and packaging technologies. The report will provide recommendations on site-of-use controlled substance disposal products and packaging technologies, including Federal oversight and evaluation of product efficacy. The House of Representatives passed the bill on June 19, 2018. Karen L. Haas is the Clerk."
}